Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer
- 30 April 2004
- Vol. 63 (4), 732-736
- https://doi.org/10.1016/j.urology.2003.11.016
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- HIGH DOSE BICALUTAMIDE FOR ANDROGEN INDEPENDENT PROSTATE CANCER: EFFECT OF PRIOR HORMONAL THERAPYJournal of Urology, 1998
- Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.Journal of Clinical Oncology, 1997
- Characterization of Patients with Androgen-Independent Prostatic Carcinoma Whose Serum Prostate Specific Antigen Decreased Following Flutamide WithdrawalJournal of Urology, 1996
- The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancerCancer, 1995
- Hormone-refractory (D3) prostate cancer: Refining the conceptUrology, 1995
- Prostate Specific Antigen after Gonadal Androgen Withdrawal and Deferred Flutamide TreatmentJournal of Urology, 1995
- Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancerAmerican Journal Of Medicine, 1995
- Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1993
- Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal SyndromeJournal of Urology, 1993
- The Response of Metastatic Adenocarcinoma of the Prostate to Exogenous TestosteroneJournal of Urology, 1981